Multilamellar lipid vesicle compositions and methods of use
AssigneeVedantra Pharmaceuticals, Inc.
InventorsAdrienne LI, Jackson EBY, Peter C. DEMUTH
Life of this patent
Estimating the term…
Abstract
The present invention provides novel and inventive drug delivery systems with higher loading capability, a capacity to sequester high tumors levels of both hydrophobic and hydrophilic agents simultaneously, and longer release profiles. Some aspects of these delivery systems include compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as inter-bilayer-crosslinked multilamellar vesicles or ICMV) covalently conjugated to an agent (e.g., an antigen).
Claims136
A composition comprising:
- (a) a multilamellar lipid vesicle having crosslinks between lipid bilayers;
- and
- (b) one or more mutant human papilloma virus (HPV) peptides;
- wherein at least one of said one or more mutant HPV peptides is conjugated to a lipid of said multilamellar lipid vesicle.
A composition comprising:
- a multilamellar lipid vesicle having crosslinks between lipid bilayers comprising one or more first mutant HPV peptides, and one or more second mutant HPV peptides,
- wherein at least one of said first mutant HPV peptides is conjugated to a first lipid of said multilamellar lipid vesicle,
- wherein at least one of said second mutant HPV peptides is conjugated to a second lipid of said multilamellar lipid vesicle, and
- wherein said first and second mutant HPV peptides are different.
A composition comprising:
- (a) a multilamellar lipid vesicle having crosslinks between lipid bilayers;
- and
- (b) one or more agents;
- wherein said one or more agents are not terminal-cysteine-bearing antigens;
- and
- wherein at least one molecule of said one or more agents is conjugated to a lipid of said multilamellar lipid vesicle.
A composition comprising:
- (a) a multilamellar lipid vesicle having crosslinks between lipid bilayers;
- and
- (b) one or more agents;
- wherein at least one molecule of said one or more agents is conjugated to a lipid of said multilamellar lipid vesicle, and
- wherein said conjugation does not comprise a cysteine.
A composition comprising:
- (a) a multilamellar lipid vesicle having crosslinks between lipid bilayers;
- and
- (b) one or more agents;
- wherein at least one molecule of said one or more agents is conjugated to a lipophilic moiety.
A method comprising administering to a subject in need thereof, 1) a multilamellar lipid vesicle having crosslinks between lipid bilayers comprising one or more mutant HPV peptides, and 2) one or more immunomodulators, wherein said immunomodulator is not a CT-011 antibody.
A method comprising
- (a) contacting a functionalized lipid with a functionalized agent to form liposomes comprising said lipid conjugated to said agent;
- (b) contacting said liposomes comprising lipids conjugated to said agent with a divalent cation to form fused liposomes;
- and
- (c) contacting said fused liposomes with a crosslinker to form multilamellar lipid vesicles having crosslinks between lipid bilayers comprising lipids conjugated to said agent,
- wherein said functionalized agent is not a terminal-cysteine-bearing antigen.
A kit comprising:
- (i) a multilamellar lipid vesicle having crosslinks between lipid bilayers comprising one or more agents,
- (ii) one or more immunomodulators, and
- (iii) instructions for administering (i) and (ii) to a subject having a disease,
- wherein said agent is not a terminal-cysteine-bearing antigen, and
- wherein said immunomodulator is not a CT-011 antibody.
A kit comprising:
- (i) a multilamellar lipid vesicle having crosslinks between lipid bilayers comprising one or more agents, and
- (ii) instructions for administering (i) with one or more immunomodulators to a subject having a disease,
- wherein said agent is not a terminal-cysteine-bearing antigen, and
- wherein said immunomodulator is not a CT-011 antibody.
A kit comprising:
- (i) one or more immunomodulators, and
- (ii) instructions for administering (i) with a multilamellar lipid vesicle having crosslinks between lipid bilayers comprising one or more agents to a subject having a disease,
- wherein said agent is not a terminal-cysteine-bearing antigen, and
- wherein said immunomodulator is not a CT-011 antibody.
Dependencies are inferred from the claim text.